company background image
PROG

Prostatype Genomics OM:PROGEN Stock Report

Last Price

kr2.15

Market Cap

kr49.1m

7D

-16.7%

1Y

-82.1%

Updated

02 Oct, 2022

Data

Company Financials +
PROGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PROGEN Stock Overview

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests.

Prostatype Genomics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prostatype Genomics
Historical stock prices
Current Share Pricekr2.15
52 Week Highkr12.48
52 Week Lowkr1.91
Beta0
1 Month Change9.14%
3 Month Change-29.51%
1 Year Change-82.11%
3 Year Changen/a
5 Year Changen/a
Change since IPO-69.29%

Recent News & Updates

Shareholder Returns

PROGENSE BiotechsSE Market
7D-16.7%10.3%0.5%
1Y-82.1%-31.3%-27.6%

Return vs Industry: PROGEN underperformed the Swedish Biotechs industry which returned -31.3% over the past year.

Return vs Market: PROGEN underperformed the Swedish Market which returned -27.6% over the past year.

Price Volatility

Is PROGEN's price volatile compared to industry and market?
PROGEN volatility
PROGEN Average Weekly Movement9.4%
Biotechs Industry Average Movement8.1%
Market Average Movement6.9%
10% most volatile stocks in SE Market11.6%
10% least volatile stocks in SE Market4.3%

Stable Share Price: PROGEN is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PROGEN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20074Fredrik Perssonhttps://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision.

Prostatype Genomics Fundamentals Summary

How do Prostatype Genomics's earnings and revenue compare to its market cap?
PROGEN fundamental statistics
Market Capkr49.15m
Earnings (TTM)-kr22.79m
Revenue (TTM)kr1.43m

34.4x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PROGEN income statement (TTM)
Revenuekr1.43m
Cost of Revenuekr11.49m
Gross Profit-kr10.06m
Other Expenseskr12.72m
Earnings-kr22.79m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 10, 2022

Earnings per share (EPS)-1.00
Gross Margin-703.69%
Net Profit Margin-1,593.28%
Debt/Equity Ratio4.6%

How did PROGEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PROGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PROGEN?

Other financial metrics that can be useful for relative valuation.

PROGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue28.9x
Enterprise Value/EBITDA-1.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PROGEN's PS Ratio compare to its peers?

PROGEN PS Ratio vs Peers
The above table shows the PS ratio for PROGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average26x
DEX Dextech Medical
19.7xn/akr61.4m
GEAN Genetic Analysis
2.1x34.1%kr42.4m
ABERA Abera Bioscience
39.3xn/akr58.5m
LPGO Lipigon Pharmaceuticals
42.8x-7.2%kr31.4m
PROGEN Prostatype Genomics
34.4x73.9%kr49.1m

Price-To-Sales vs Peers: PROGEN is expensive based on its Price-To-Sales Ratio (34.4x) compared to the peer average (26x).


Price to Earnings Ratio vs Industry

How does PROGEN's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Sales vs Industry: PROGEN is expensive based on its Price-To-Sales Ratio (34.4x) compared to the Swedish Biotechs industry average (19x)


Price to Sales Ratio vs Fair Ratio

What is PROGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PROGEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio34.4x
Fair PS Ratio0.01x

Price-To-Sales vs Fair Ratio: PROGEN is expensive based on its Price-To-Sales Ratio (34.4x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Share Price vs Fair Value

What is the Fair Price of PROGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PROGEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PROGEN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Prostatype Genomics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


78.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PROGEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).

Earnings vs Market: PROGEN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PROGEN is expected to become profitable in the next 3 years.

Revenue vs Market: PROGEN's revenue (73.9% per year) is forecast to grow faster than the Swedish market (10.8% per year).

High Growth Revenue: PROGEN's revenue (73.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PROGEN is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Prostatype Genomics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-21.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PROGEN is currently unprofitable.

Growing Profit Margin: PROGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PROGEN is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.

Accelerating Growth: Unable to compare PROGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PROGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16.7%).


Return on Equity

High ROE: PROGEN has a negative Return on Equity (-99.24%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Prostatype Genomics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PROGEN's short term assets (SEK10.9M) exceed its short term liabilities (SEK4.7M).

Long Term Liabilities: PROGEN's short term assets (SEK10.9M) exceed its long term liabilities (SEK866.7K).


Debt to Equity History and Analysis

Debt Level: PROGEN has more cash than its total debt.

Reducing Debt: PROGEN's debt to equity ratio has reduced from 14.2% to 4.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PROGEN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PROGEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22.1% each year


Discover healthy companies

Dividend

What is Prostatype Genomics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Prostatype Genomics Dividend Yield vs Market
How does Prostatype Genomics dividend yield compare to the market?
SegmentDividend Yield
Company (Prostatype Genomics)n/a
Market Bottom 25% (SE)1.8%
Market Top 25% (SE)6.1%
Industry Average (Biotechs)2.2%
Analyst forecast in 3 Years (Prostatype Genomics)n/a

Notable Dividend: Unable to evaluate PROGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PROGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PROGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PROGEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PROGEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Fredrik Persson

5.75yrs

Tenure

Mr. Fredrik Persson has been Chief Executive Officer of Prostatype Genomics AB (publ) since 2017 and serves as its Managing Director. He has years of international life science industry experience in lead...


Leadership Team

Experienced Management: PROGEN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: PROGEN's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

OM:PROGEN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Dec 21Buykr72,080Fredrik PerssonIndividual8,000kr9.01
29 Nov 21Buykr46,475Aj Lundberg KapitalfÖRvaltning AbCompany5,000kr9.30
24 Nov 21Buykr74,900Fredrik PerssonIndividual7,000kr10.70
22 Nov 21Buykr99,610Aj Lundberg KapitalfÖRvaltning AbCompany10,000kr9.96
22 Nov 21Buykr108,000Michael HaggmanIndividual10,000kr10.80
22 Nov 21Buykr108,000Fredrik PerssonIndividual10,000kr10.80
22 Nov 21Buykr108,300Hakan EnglundIndividual10,000kr10.83

Ownership Breakdown

What is the ownership structure of PROGEN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders882,6453.9%
Private Companies1,293,1245.7%
VC/PE Firms3,079,91113.5%
General Public17,603,81777.0%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.5%.


Top Shareholders

Top 8 shareholders own 22.99% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.47%
Creathor Venture Management GmbH
3,079,911SEK6.6m0%no data
4.33%
ID Invest AB
989,015SEK2.1m0%no data
3.14%
Hakan Englund
717,605SEK1.5m0%no data
1.33%
Aj Lundberg KapitalfÖRvaltning Ab
304,109SEK653.8k0%no data
0.59%
Fredrik Persson
134,715SEK289.6k0%no data
0.11%
Michael Haggman
24,817SEK53.4k0%no data
0.016%
Lidi Xu
3,672SEK7.9k0%no data
0.008%
Dilruba Ahmed
1,836SEK3.9k0%no data

Company Information

Prostatype Genomics AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Prostatype Genomics AB (publ)
  • Ticker: PROGEN
  • Exchange: OM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr49.148m
  • Shares outstanding: 22.86m
  • Website: https://www.prostatypegenomics.com

Number of Employees


Location

  • Prostatype Genomics AB (publ)
  • Industrivägen 19
  • Solna
  • Stockholm County
  • 171 48
  • Sweden


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PROGENOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKNov 2020
PGODB (Deutsche Boerse AG)YesShare CapitalDEEURNov 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.